Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial

Authors:

Abstract
No abstract available
Funding Information
  • Gilead Sciences

This publication has 13 references indexed in Scilit: